Doripenem-d4 (sodium salt)

Doripenem-d4 is intended for use as an internal standard for the quantification of doripenem (Item No. 16934) by GC- or LC-MS. Doripenem is a broad-spectrum antibiotic in the β-lactam subclass known as carbapenems.1,2 It is active against Gram-negative and Gram-positive bacteria, including S. aureus, S. pneumoniae, E. coli, and K. pneumoniae (MICs = 0.03-0.06, 0.016-0.06, <0.015-0.3, and 0.03-0.06 µg/ml, respectively).1,2,3,4 Doripenem reduces the number of viable bacteria in mouse lung in a model of chronic P. aeruginosa respiratory tract infection when administered at a dose of 100 mg/kg per day.5 It inhibits bacterial cell wall synthesis by forming stable acyl enzymes with penicillin-binding proteins, thereby inactivating them.2 Formulations containing doripenem have been used in the treatment of bacterial infections.WARNING This product is not for human or veterinary use.

[1] MANDELL L. Doripenem: a new carbapenem in the treatment of nosocomial infection.[J]. Clinical Infectious Diseases, 2009, 49 Suppl 1: S1-3. DOI: 10.1086/599809
[2] Doripenem[J]. Reactions Weekly, 2015, 19 1: 94. DOI: 10.1007/s40278-015-9917-1
[3] KRISZTINA M PAPP-WALLACE. Carbapenems: past, present, and future.[J]. ACS Applied Energy Materials, 2011: 4943-4960. DOI: 10.1128/aac.00296-11
[4] ALI A EL SOLH  Ahmad A. Update on the treatment of Pseudomonas aeruginosa pneumonia.[J]. Journal of Antimicrobial Chemotherapy, 2009, 64 2: 229-238. DOI: 10.1093/jac/dkp201
[5] NOBUKO ARAKI. In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model[J]. Journal of Infection and Chemotherapy, 2011, 17 3: Pages 318-321. DOI: 10.1007/s10156-010-0166-1